Drug interactions between Brilinta and YSP Aspirin
| Results for the following 2 drugs: |
|---|
| Brilinta (ticagrelor) |
| YSP Aspirin (aspirin) |
Interactions between your selected drugs
aspirin ↔ ticagrelor
Applies to:YSP Aspirin (aspirin) and Brilinta (ticagrelor)
ADJUST DOSE: Use of high maintenance dosages of aspirin may decrease the effectiveness of ticagrelor in preventing thrombotic events in patients with acute coronary syndromes. The underlying biological mechanism has not been established. Data from PLATO, a large, randomized, double-blind efficacy and safety comparison study with clopidogrel, suggest that the efficacy of ticagrelor is associated with aspirin dosage during maintenance therapy. Patients who received a low maintenance dosage (75 to 150 mg daily) of aspirin benefited more than those who received a high maintenance dosage (above 300 mg daily). Because data for the high maintenance dosages of aspirin do not provide conclusive evidence of efficacy of ticagrelor relative to clopidogrel, the dosage of aspirin should be limited during maintenance dual antiplatelet therapy with ticagrelor. In drug interaction studies, coadministration of ticagrelor with aspirin did not have any effect on the plasma levels of ticagrelor or its active metabolite.
MANAGEMENT: Following the initial loading dose (usually 325 mg) of aspirin, a daily maintenance dose of 75 to 100 mg is recommended by the manufacturer to be used with ticagrelor.
See also...
Drug Interaction Classification
The classifications below are a guideline only. The relevance of a particular drug interaction to a specific patient is difficult to determine using this tool alone given the large number of variables that may apply.
| Major | Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. |
| Moderate | Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. |
| Minor | Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. |
Do not stop taking any medications without consulting your healthcare provider.
Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. Multum's drug information does not endorse drugs, diagnose patients, or recommend therapy. Multum's drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2012 Multum Information Services, Inc. The information in contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.
